StockData
Thermo Fisher Scientific Inc. logo

Thermo Fisher Scientific Inc.

TMONYSEMeasuring & Controlling Devices, NECFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Oct 30, 2026Score 12/3027% above fair value
$682.65−14.35 (-2.06%)

Close on Nov 2, 2026Market cap $252.41BP/E 36.0Yield 0.25%

Thermo Fisher Scientific Laboratory Products and Biopharma Services Segment by Quarter

Laboratory Products and Biopharma Services Segment (Total Segment Revenue) ($M)

QuarterlyAnnual

Thermo Fisher Scientific Laboratory Products and Biopharma Services Segment: $6,863M in Q3 2026, up 15.0% from a year earlier. That is the highest of the 19 quarters on record here.

Latest, Q3 2026
6,863
Period ended Sep 30, 2026
Change on a year earlier
+15.0%
5,970 in Q3 2025
History
19 quarters
Since Q1 2022
Sources
7
Documents cited below

Where the Q3 2026 figure comes from

“LPBS: Revenues 5,640 5,995 5,970 6,379 23,984 6,036 6,693 6,863”

Source: Q3 2026 Reconciliation of Financial Information ↗

Includes 4 operating businesses: Pharma Services (Patheon CDMO), Clinical Research (PPD CRO), Research & Safety Market Channel (Fisher Scientific), and Laboratory Products.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLaboratory Products and Biopharma Services Segment (Total Segment Revenue) ($M)Year on yearSource
Q3 2026Sep 30, 20266,863+15.0%Q3 2026 Reconciliation of Financial Information ↗
Q2 2026Jun 30, 20266,693+11.6%Q3 2026 Reconciliation of Financial Information ↗
Q1 2026Mar 31, 20266,036+7.0%Q3 2026 Reconciliation of Financial Information ↗
Q4 2025Dec 31, 20256,379+7.5%Q3 2026 Reconciliation of Financial Information ↗
Q3 2025Sep 30, 20255,970+4.0%Q3 2026 Reconciliation of Financial Information ↗
Q2 2025Jun 30, 20255,995+4.1%Q3 2026 Reconciliation of Financial Information ↗
Q1 2025Mar 31, 20255,640-1.5%Q3 2026 Reconciliation of Financial Information ↗
Q4 2024Dec 31, 20245,936+3.8%Q4 & FY2025 Reconciliation of Financial Information ↗
Q3 2024Sep 30, 20245,740+0.2%Q4 & FY2025 Reconciliation of Financial Information ↗
Q2 2024Jun 30, 20245,758-1.3%Q4 & FY2025 Reconciliation of Financial Information ↗
Q1 2024Mar 31, 20245,723-0.7%Q4 & FY2025 Reconciliation of Financial Information ↗
Q4 2023Dec 31, 20235,719-3.8%Q4 & FY2024 Reconciliation of Financial Information ↗
Q3 2023Sep 30, 20235,728+2.6%Q4 & FY2024 Reconciliation of Financial Information ↗
Q2 2023Jun 30, 20235,831+5.3%Q4 & FY2024 Reconciliation of Financial Information ↗
Q1 2023Mar 31, 20235,763+5.9%Q4 & FY2024 Reconciliation of Financial Information ↗
Q4 2022Dec 31, 20225,947–SEC Form 8-K (8k_2023Q4, filed 2024-01-31) ↗

Breakdown

What makes up laboratory Products and Biopharma Services Segment

Cite this data

StockData. (2026). Thermo Fisher Scientific Laboratory Products and Biopharma Services Segment ($M), quarterly Q1 2022–Q3 2026 [Data set]. Compiled from Thermo Fisher Scientific SEC filings and investor materials. https://stockdatahq.com/stocks/tmo/kpis/rev-seg-lpbs

See every metric in the Thermo Fisher Scientific KPI table. Data updated Oct 29, 2026.